Factors associated with progression of interstitial fibrosis in renal transplant patients receiving tacrolimus and mycophenolate mofetil

Transplantation

Volumn 88, Issue 7, 2009, Pages 897-903

  Rush, David N ^a   Cockfield, Sandra M ^b   Nickerson, Peter W ^a   Arlen, Dianne J ^c   Boucher, Anne ^d   Busque, Stephan ^e   Girardin, Catherine E ^f   Knoll, Gregory A ^g   Lachance, Jean Guy ^h   Landsberg, David N ⁱ   Shapiro, R Jean ^j   Shoker, Ahmed ^k   Yilmaz, Serdar ^l  

^a HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c ST JOSEPH S HOSPITAL   (Canada)

^d MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^e STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^f NOTRE DAME HOSPITAL   (Canada)

^g UNIVERSITY OF OTTAWA   (Canada)

^h LAVAL UNIVERSITY   (Canada)

ⁱ ST PAUL S HOSPITAL   (Canada)

^j Gordon and Leslie Diamond Health Care Centre Vancouver Coastal Health   (Canada)

^k Saskatoon Health Region St Pauls Hospital   (Canada)

^l FOOTHILLS HOSPITAL   (Canada)

more..

Author keywords

Ace inhibition; Biopsy; Interstitial fibrosis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; IRBESARTAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAMIPRIL; TACROLIMUS;

ADULT; ARTICLE; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; GLOMERULONEPHRITIS; GRAFT RECIPIENT; HUMAN; HYPERTENSION; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY DONOR; KIDNEY FIBROSIS; KIDNEY FUNCTION TEST; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION;

ADULT; BIOPSY; CADAVER; DISEASE PROGRESSION; FEMALE; FIBROSIS; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISONE; REGRESSION ANALYSIS; TACROLIMUS; TISSUE DONORS;

EID: 73249124136     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181b723f4     Document Type: Article

References (27)

1. Rush D, Arlen D, Boucher A, et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: A randomized study. Am J Transplant 2007; 7: 2538. (Pubitemid 47561621)
2. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713. (Pubitemid 29082898)
3. Wolf G. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-ß pathway. Kidney Int 2006; 70: 1914. (Pubitemid 44863378)
4. Fogo AB. Mechanisms of progression of chronic kidney disease. Pediatr Nephrol 2007; 22: 2011.
5. Boots JM, van Duiijnhoven EM, Christiaans MH, et al. Single centre experience with tacrolimus versus cyclosporine Neoral in renal transplant recipients. Transpl Int 2001; 14: 370.
6. Cosio FG, Grande JP, Larson TS, et al. Kidney allograft fibrosis and atrophy early after living donor transplantation. Am J Transplant 2005; 5: 1130.
7. Cosio FG, Amer H, Grande JP, et al. Comparison of low versus high tacrolimus levels in kidney transplantation: Assessment of efficacy by protocol biopsies. Transplantation 2007; 83: 411. (Pubitemid 46667844)
8. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562. (Pubitemid 350294223)
9. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
10. Nankivell BJ, Borrows RJ, Fung CL, et al. Delta analysis of posttransplantation tubulointerstitial damage. Transplantation 2004; 78: 434.
11. Moreso F, Serón D, Carrera M, et al. Baseline immunosuppression is associated with histological findings in early protocol biopsies. Transplantation 2004; 78: 1064. (Pubitemid 39391871)
12. Naesens M, Lerut E, Damme BV, et al. Tacrolimus exposure and the evolution of renal allograft histology in the first year after transplantation. Am J Transplant 2007; 7: 2114. (Pubitemid 47247039)
13. Serón D, Moreso F, Bover J, et al. Early protocol renal allograft biopsies and graft outcome. Kidney Int 1997; 51: 310. (Pubitemid 27064552)
14. Grimm PC, Nickerson P, Gough J, et al. Computerized image analysis of Sirius Red-stained renal allograft biopsies as a surrogate marker to predict long-term allograft function. J Am Soc Nephrol 2003; 14: 1662. (Pubitemid 36687070)
15. Nickerson PW, Jeffery J, Gough J, et al. Identification of clinical and histopathological risk factors for diminished renal function 2 years post-transplant. J Am Soc Nephrol 1998; 9: 482. (Pubitemid 28122875)
16. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4: 1776. (Pubitemid 39434437)
17. Pontrelli P, Rossini M, Infante B, et al. Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Transplantation 2008; 85: 125.
18. Dean PG, Grande JP, Sethi S, et al. Kidney transplantation histology after one year of continuous therapy with sirolimus compared with tacrolimus. Transplantation 2008; 85: 1212. (Pubitemid 351590201)
19. Mulay AV, Cockfield S, Stryker R, et al. Conversion from calcineurin inhibitors to sirolimus for chronic renal dysfunction: A systematic review of the evidence. Transplantation 2006; 82: 1153. (Pubitemid 44748017)
20. Slattery C, Campbell E, McMorrow T, et al. Cyclosporine A-induced renal fibrosis: A role for epithelial-mesenchymal transition. Am J Pathol 2005; 167: 395. (Pubitemid 43026096)
21. Vongwiwatana A, Tasanarong A, Rayner DC, et al. Epithelial to mesenchymal transition during late deterioration of human, kidney transplants: The role of tubular cells in fibrogenesis. Am J Transplant 2005; 5: 1367. (Pubitemid 40839427)
22. Campistol JM, Inigo P, Jimenez W, et al. Losartan decreases plasma levels of TGF-beta 1 in transplant patients with chronic allograft nephropathy. Kidney hit 1999; 56: 714. (Pubitemid 29353172)
23. Tylicki L, Biedunkiewicz B, Chamienia A, et al. Renal allograft protection with angiotensin II type 1 receptor antagonists. Am J Transplant 2007; 7: 243. (Pubitemid 44952879)
24. El-Agroudy AE, Hassan NA, Foda MA, et al. Effect of angiotensin receptor blocker on plasma levels of TGF-ßl and interstitial fibrosis in hypertensive kidney transplant patients. Am J Nephrol 2003; 23: 300.
25. Ishikawa A, Tanaka M, Ohta N, et al. Prevention of interstitial fibrosis of renal allograft by angiotensin II blockade. Transplant Proc 2006; 38: 3498. (Pubitemid 44908469)
26. Heinze G, Mitterbauer C, Regele H, et al. Angiotensin-Converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006; 17: 889.
27. Opelz G, Zeier M, Laux G, et al. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: A collaborative transplant study report. JAm Soc Nephrol 2006; 17: 3257. (Pubitemid 44707788)